UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Annals of oncology, 2020-05, Vol.31 (5), p.609-618

2020

Volltextzugriff (PDF)

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Annals of oncology, 2019-04, Vol.30, p.ii77-ii77

2019

Volltextzugriff (PDF)

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Leukemia, 2002-12, Vol.16 (12), p.2358-2365

2002

Volltextzugriff (PDF)

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

Leukemia, 2003-09, Vol.17 (9), p.1700-1706

2003

Volltextzugriff (PDF)

1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial

Annals of oncology, 2021-09, Vol.32, p.S989-S990

2021

Volltextzugriff (PDF)

A randomized multicenter open label phase ii study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

Annals of hematology, 2003-11, Vol.82 (11), p.716-720

2003

Volltextzugriff (PDF)

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Blood, 2006-02, Vol.107 (3), p.1116-1123

2006

Volltextzugriff (PDF)

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-α (IFN-α) in philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

Leukemia, 2003-10, Vol.17 (10), p.1919-1924

2003

Volltextzugriff (PDF)

P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy

Annals of oncology, 2015-06, Vol.26, p.iv89

2015

Volltextzugriff (PDF)

Risk/MRD adapted GMALL trials in adult ALL

Annals of hematology, 2004, Vol.83 Suppl 1, p.S129-S131

2004

Volltextzugriff (PDF)

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Annals of oncology, 2019-11, Vol.30, p.ix157-ix158

2019

Volltextzugriff (PDF)

1491P - PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30, p.v611-v611

2019

Volltextzugriff (PDF)

PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30, p.v611

2019

Volltextzugriff (PDF)

Early modifications of host cell gene expression induced by HIV-1

AIDS (London), 1998-04, Vol.12 (6), p.563-570

1998

Volltextzugriff (PDF)

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S217-S217

2019

Volltextzugriff (PDF)

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells

AIDS (London), 1999-02, Vol.13 (2), p.167-175

1999

Volltextzugriff (PDF)

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2001-10, Vol.28 (7), p.721-724

2001

Volltextzugriff (PDF)

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2003-04, Vol.31 (7), p.611-614

2003

Volltextzugriff (PDF)

Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate

Clinical cancer research, 2003-10, Vol.9 (13), p.4674-4681

2003

Volltextzugriff (PDF)

Knockdown of ERM family member moesin in host cells increases HIV type 1 replication

AIDS research and human retroviruses, 2011-12, Vol.27 (12), p.1317

2011

Volltextzugriff (PDF)

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Blood, 2005-07, Vol.106 (2), p.458-463

2005

Volltextzugriff (PDF)

Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination

Medical microbiology and immunology, 2003-11, Vol.192 (4), p.193-195

2003

Volltextzugriff (PDF)

Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN)

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.9603-9603

2008

Volltextzugriff (PDF)

1491PPD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5025-5025

2007

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(68)

Publikationsform

Artikel
(71)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Biological And Medical Sciences
(32)
Humans
(31)
Medical Sciences
(18)
Fundamental And Applied Biological Sciences. Psychology
(16)
Female
(11)
Hematology
(11)
Male
(10)
Middle Aged
(10)
Adult
(9)
Animals
(9)
Benzamides
(9)
Biochemistry & Molecular Biology
(9)
Imatinib Mesylate
(9)
Immunology
(9)
Hematologic And Hematopoietic Diseases
(7)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(7)
Molecular And Cellular Biology
(7)
Oncology
(7)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer

Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph ALL) during imatinib treatment

1264P Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia

Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-α (IFN-α) in philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

P-304 RECORA - A national non-interventional study to assess efficacy and safety of regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy

Risk/MRD adapted GMALL trials in adult ALL

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

1491P - PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

PD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Early modifications of host cell gene expression induced by HIV-1

OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial

Differential expression profiles of apoptosis-affecting genes in HIV-infected cell lines and patient T cells

Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation

Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation

Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate

Knockdown of ERM family member moesin in host cells increases HIV type 1 replication

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL)

Long-term benzimidazole treatment of alveolar echinococcosis with hematogenic subcutaneous and bone dissemination

Comparison of kidney cancer symptoms and quality of life (QoL) in renal cell cancer (RCC) patients (pts) receiving sorafenib vs interferon-α (IFN)

1491PPD-L1 expression in primary tumour vs metastatic samples in the phase III MYSTIC study in first-line metastatic (m) NSCLC

Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results

Suchergebnisse filtern